Redeye provides a research update on Faron Pharmaceuticals following the company’s recent annual report and clinical progress with lead candidate Bexmarilimab. We make some adjustments to our overall estimates following a revision of our model. Accordingly, as we continue to see a compelling case rooted in an exciting pipeline, we revise our fair value range and raise our base case valuation.